Cover Image
市場調查報告書

Genelux Corporation:產品平台分析

Genelux Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 301291
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
Genelux Corporation:產品平台分析 Genelux Corporation - Product Pipeline Review - 2015
出版日期: 2015年05月27日 內容資訊: 英文 30 Pages
簡介

Genelux Corporation,是開發·商品化癌症·發炎性疾病所用之診斷·治療用解決方案的生物醫藥品公司。在腫瘤溶解性病毒療法領域進行研究活動。

本報告提供Genelux Corporation之調查分析,提供您治療藥的開發平台最新資訊,加上各開發階段比較分析,藥物標的·作用機制·給藥途徑·各分子類型的治療藥評估,也包含最新消息和新聞稿,後期階段·中止的計劃等系統性資訊。

目錄

Genelux Corporation的基本資料

  • Genelux Corporation概要
  • 主要資訊
  • 企業資料

Genelux Corporation:研究開發概要

  • 主要的治療領域

Genelux Corporation:開發平台檢驗

  • 開發中產品:各開發階段
  • 開發中產品:單獨療法

Genelux Corporation:開發中產品的概要

  • 臨床階段的開發中產品
  • 初期階段的開發中產品

Genelux Corporation:藥物簡介

  • GLONC-1
  • GLONC-2
  • GLONC-3
  • GLONC-4
  • GLV-1h164
  • GLV-1h237

Genelux Corporation:開發平台分析

  • 開發中產品:標的別
  • 開發中產品:各給藥途徑
  • 開發中產品:各分子類型
  • 開發中產品:各作用機制

Genelux Corporation:開發平台的最新趨勢

Genelux Corporation:暫停中的計劃

Genelux Corporation:所在地與子公司

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07122CDB

Summary

Global Markets Direct's, 'Genelux Corporation - Product Pipeline Review - 2015', provides an overview of the Genelux Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Genelux Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Genelux Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Genelux Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Genelux Corporation's pipeline products

Reasons to buy

  • Evaluate Genelux Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Genelux Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Genelux Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Genelux Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Genelux Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Genelux Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Genelux Corporation Snapshot
    • Genelux Corporation Overview
    • Key Information
    • Key Facts
  • Genelux Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Genelux Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Genelux Corporation - Pipeline Products Glance
    • Genelux Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Genelux Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Genelux Corporation - Drug Profiles
    • GLONC-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLONC-2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLONC-3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLONC-4
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLV-1h164
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GLV-1h237
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Genelux Corporation - Pipeline Analysis
    • Genelux Corporation - Pipeline Products by Target
    • Genelux Corporation - Pipeline Products by Route of Administration
    • Genelux Corporation - Pipeline Products by Molecule Type
    • Genelux Corporation - Pipeline Products by Mechanism of Action
  • Genelux Corporation - Recent Pipeline Updates
  • Genelux Corporation - Dormant Projects
  • Genelux Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Genelux Corporation, Key Information
  • Genelux Corporation, Key Facts
  • Genelux Corporation - Pipeline by Indication, 2015
  • Genelux Corporation - Pipeline by Stage of Development, 2015
  • Genelux Corporation - Monotherapy Products in Pipeline, 2015
  • Genelux Corporation - Phase II, 2015
  • Genelux Corporation - Phase I, 2015
  • Genelux Corporation - Preclinical, 2015
  • Genelux Corporation - Pipeline by Target, 2015
  • Genelux Corporation - Pipeline by Route of Administration, 2015
  • Genelux Corporation - Pipeline by Molecule Type, 2015
  • Genelux Corporation - Pipeline Products by Mechanism of Action, 2015
  • Genelux Corporation - Recent Pipeline Updates, 2015
  • Genelux Corporation - Dormant Developmental Projects,2015
  • Genelux Corporation, Subsidiaries

List of Figures

  • Genelux Corporation - Pipeline by Top 10 Indication, 2015
  • Genelux Corporation - Pipeline by Stage of Development, 2015
  • Genelux Corporation - Monotherapy Products in Pipeline, 2015
  • Genelux Corporation - Pipeline by Top 10 Route of Administration, 2015
  • Genelux Corporation - Pipeline by Top 10 Molecule Type, 2015
Back to Top